迪哲医药拟发行H股股票并在香港联交所上市

Core Viewpoint - Dizhihua Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and brand image [1] Group 1: Company Announcement - On December 24, Dizhihua Pharmaceutical held its 18th meeting of the second board of directors, approving the proposal for issuing H-shares [1] - The company aims to deepen its global strategy, enhance its international brand image, and improve its core competitiveness through this listing [1] Group 2: Financial Performance - For the first three quarters of 2025, Dizhihua Pharmaceutical reported revenue of approximately 586 million yuan, with a corresponding net profit attributable to shareholders of approximately -580 million yuan [1]